Ogeda is developing a drug called fezolinetant to treat hot flashes and night sweats caused by menopause, according to the report.
Astellas will pay $533 million upfront, along with $320 in milestone payments for the development of fezolinetant.
“The transaction fits with our strategy to deliver innovative drugs in therapeutic areas with high unmet medical needs,” Astellas President and CEO Yoshihiko Hatanaka said in a news release.
More articles on supply chain:
Viewpoint: US should strengthen existing laws to lower drug prices — not make new ones
Mexico border tax could lead to medical device shortages: 4 things to know
How SSM Health’s pharmacy concierge program helps patients manage high drug costs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
